20-069 - Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative TreatmentStatus: open
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2)
Treatment for Hepatocellular Carcinoma
This clinical trial is for patients who have been diagnosed with a type of liver cancer (Hepatocellular Carcinoma (HCC) and patients are at high risk of recurrence after curative hepatic resection or ablation. The reason for the study is to find more effective treatment for HCC after curative resection or ablation.
SponsorsThis trial is sponsored by Astra Zeneca.
Interested in Clinical Trial?
Providers Associated With This Trial
- Moh'd Khushman, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Clinical Oncology
- Sachin Pai, M.D., M.S.C.I.Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical Oncology
- Osama Abdul-Rahim, M.D.Interventional RadiologistAssistant Professor of Radiology